{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 452028402
| IUPAC_name = 8-[(3''R'')-3-Aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1''H''-purine-2,6-dione
| image = Linagliptin.svg
| width = 250

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|l|ɪ|n|ə|ˈ|g|l|ɪ|p|t|ɪ|n}} {{respell|LIN|ə|GLIP|tin}}
| tradename = Tradjenta, Trajenta
| Drugs.com = {{drugs.com|CDI|linagliptin}}
| MedlinePlus = a611036
| licence_EU = Trajenta
| licence_US = Linagliptin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =
| legal_AU = S4
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = ~30% ([[Cmax (pharmacology)|T<sub>max</sub>]] = 1.5 hours)
| protein_bound = 75–99% (concentration-dependent)
| metabolism = Minimal (~10% metabolized)
| metabolites = Pharmacologically inactive
| elimination_half-life = ~24 hours
| excretion = [[Feces]] (80%), [[urine]] (5%)<ref name="PI">{{cite web|title=Tradjenta (linagliptin) Tablets. Full Prescribing Information|url=http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf?DMW_FORMAT=pdf|publisher=Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA|accessdate=10 November 2016}}</ref>

<!--Identifiers-->
| IUPHAR_ligand = 6318
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 668270-12-0
| ATC_prefix = A10
| ATC_suffix = BH05
| ATC_supplemental =  
| PubChem = 10096344
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 237500
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68610
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3X29ZEJ4R2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09566
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8271879

<!--Chemical data-->
| chemical_formula =
| C=25 | H=28 | N=8 | O=2 
| molecular_weight = 472.54 g/mol
| smiles = CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = LTXREWYXXSTFRX-QGZVFWFLSA-N
}}

'''Linagliptin''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61|url=http://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf|publisher=World Health Organization|accessdate=10 November 2016|page=66}}</ref> previously known as '''BI-1356''', marketed under trade names '''Tradjenta''' ([[United States|U.S.]]) and '''Trajenta''' (worldwide)) is a [[dipeptidyl peptidase-4 inhibitor]] developed by [[Boehringer Ingelheim]] for treatment of [[diabetes mellitus type 2]].

Once-daily linagliptin was approved by the U.S. [[Food and Drug Administration]] (FDA) on 2 May 2011 for treatment of type 2 diabetes.<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/fda-approves-type-2-diabetes-drug-from-boehringer-ingelheim-and-lilly/81245092/ |title=FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly |date=3 May 2011 }}</ref> It is being marketed by Boehringer Ingelheim and [[Eli Lilly and Company|Lilly]].

==Medical uses==
Results in 2010 from a [[Phases_of_clinical_research#Phase_III|Phase III]] clinical trial of linagliptin showed that the drug can effectively reduce [[blood sugar]].<ref>{{cite news|url=http://www.genengnews.com/gen-news-highlights/four-phase-iii-trials-confirm-benefits-of-bi-s-oral-once-daily-type-2-diabetes-therapy/81243585/|title=Four Phase III Trials Confirm Benefits of BI’s Oral, Once-Daily Type 2 Diabetes Therapy|publisher=Genetic Engineering & Biotechnology News|date=28 June 2010}}</ref>

==Side effects==
Linagliptin may cause severe joint pain.<ref name="PI" /><ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm|website=FDA|accessdate=1 September 2015|date=2015-08-28}}</ref>

== Mechanism of action ==
Linagliptin belongs to a class of drugs called [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s. DPP-4 inhibitors prevent the hormone [[incretin]] from being degraded, allowing insulin to be released from the pancreatic beta cells. While incretin remains in the blood stream, the [[pancreas]] is stimulated to produce more insulin. Meanwhile, glucagon release from the pancreas is staggered, preventing glucose level increase. In other words, linagliptin, along with diet and exercise, can help the body produce more insulin and lower blood glucose. Managing blood sugar can mean a lower [[Glycated hemoglobin|HbA<sub>1c</sub>]], an index for glycemia control that theoretically correlates with glucose level in the blood. However, the use of [[Glycated hemoglobin|HbA<sub>1c</sub>]] to predict diabetes in patients can sometimes be limited due to other external factors, such as blood transfusion, acute blood loss, or drug interference. <ref>{{cite journal|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401751/#ref5/|title=Drugs affecting HbA1c levels|publisher=Indian J Endocrinol Metab.|date=2012}}</ref>

== See also ==
* [[Empagliflozin/linagliptin]]

== References ==
{{reflist}}
* {{cite journal
 | author = H. Spreitzer
 | date = September 1, 2008
 | title = Neue Wirkstoffe - BI-1356
 | journal = Österreichische Apothekerzeitung
 | issue = 18/2008
 | pages = 918
 | language = German
 }}
* {{cite journal
 | author = Wang, Y, Serradell, N, Rosa, E, Castaner, R
 | title = BI-1356
 | journal = Drugs of the Future
 | year = 2008
 | volume = 33
 | issue = 6
 | pages = 473–477
 | doi = 10.1358/dof.2008.033.06.1215244
 }}


{{Oral hypoglycemics}}

==External links==
{{Commons category}}
* [https://www.tradjenta.com/ Tradjenta official website (United States)]
* [http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/linagliptin Trajenta (Australia)]
* [http://www.boehringer-ingelheim.ca/en/human_health/our_products.html Trajenta (Canada)]
* [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002110/human_med_001482.jsp&mid=WC0b01ac058001d124 Trajenta (European Union)]
* [http://www.medindia.net/doctors/drug_information/linagliptin.htm Trajenta (India)]

[[Category:Alkynes]]
[[Category:Dipeptidyl peptidase-4 inhibitors]]
[[Category:Piperidines]]
[[Category:Quinazolines]]
[[Category:Xanthines]]